Page 1

April - June Financial summary for the quarter Net turnover amounted to SEK 0.9 ( 4.0 ) million . ● The loss before interest , tax , depreciation and amortization ( EBITDA ) amounted to SEK -17.1 ( -12.4 ) million . Basic and diluted earnings per share amounted to SEK -0.35 ( -0.52 ) and SEK -0.35 ( -0.52 ) respectively . Cash flow from operating activities amounted to SEK -21.9 ( -23.3 ) million . ● MEDIVIR AB - INTERIM REPORT JANUARY - JUNE 2021 ● Positive study results for MIV - 818 and remetinostat . Design determined for the combination study with MIV - 818 Significant events during the quarter On April 16 , it was announced that Magnus Christensen had been appointed interim CEO of Medivir . He took up his new role in connection with Medivir's AGM on May 5 , 2021 . On April 19 , it was announced that the overall results from the first part of the phase lb study with MIV - 818 were positive with a good safety and tolerability profile . Thus , the starting dose for the second part of the phase lb study could be determined . Liquid assets and short - term investments at the end of . the period amounted to SEK 247.8 ( 94.9 ) million . In May , positive results from an investigator - initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma ( SCC ) were released on clinical trials.gov . In May , the design for the upcoming phase 1b / 2a combination study with the company's leading candidate drug , MIV - 818 against liver cancer , was presented . In the study , MIV - 818 will be administered in two combinations , with either lenvatinib , a tyrosine kinase inhibitor , or pembrolizumab , an anti - PD - 1 checkpoint inhibitor . MEDIVIR January - June Financial summary for the period Net turnover amounted to SEK 10.8 ( 11.4 ) million . The loss before interest , tax , depreciation and amortization ( EBITDA ) amounted to SEK -24.3 ( -33.1 ) million . Basic and diluted earnings per share amounted to SEK -0.57 ( -1.49 ) and SEK -0.57 ( -1.49 ) respectively . Cash flow from operating activities amounted to SEK -23.3 ( -40.0 ) million . ● Significant events after the end of the period ● Liquid assets and short - term investments at the end of the period amounted to SEK 247.8 ( 94.9 ) million . In July , Malene Jensen was appointed Vice President Clinical Development . She will assume her role on September 6 , 2021 . In August , it was announced that data from the MIV 818 phase 1b study will be presented at the ESMO Congress in September . In August , the positive results from the phase II study with remetinostat against basal cell carcinoma were published in the scientific journal Clinical Cancer Research . In August , it was announced that Medivir , through a renegotiated multi - party agreement , strengthens the business development potential for remetinostat . Medivir in brief Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high . The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients . Medivir is focusing on the development of MIV - 818 , a pro - drug designed to selectively treat liver cancer cells and to minimize side effects . Collaborations and partnerships are important parts of Medivir's business model , and the drug development is conducted either by Medivir or in partnership . Birinapant , a SMAC mimetic , is exclusively outlicensed to IGM Biosciences ( Nasdaq : IGMS ) to be developed in combination with IGM - antibodies for the treatment of solid tumors . Medivir's share ( ticker : MVIR ) is listed on Nasdaq Stockholm's Small Cap list . www.medivir.com Medivir AB ( publ ) , 556238-4361 . PO Box 1086 , SE - 141 22 Huddinge , Sweden . Telephone +46 ( 0 ) 8-5468 3100 . info@medivir.se | www.medivir.com 1